GeoVax Labs, Inc. (NASDAQ:GOVX) Sees Significant Increase in Short Interest

GeoVax Labs, Inc. (NASDAQ:GOVX) was the recipient of a large growth in short interest in the month of March. As of March 31st, there was short interest totalling 815,200 shares, a growth of 33.5% from the March 15th total of 610,600 shares. Approximately 9.2% of the company’s stock are short sold. Based on an average daily trading volume, of 587,800 shares, the days-to-cover ratio is presently 1.4 days.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in shares of GeoVax Labs during the 4th quarter valued at about $104,000. Virtu Financial LLC bought a new position in GeoVax Labs during the third quarter valued at approximately $97,000. Geode Capital Management LLC boosted its holdings in GeoVax Labs by 59.0% in the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares during the last quarter. Finally, Northern Trust Corp bought a new stake in GeoVax Labs in the 4th quarter worth approximately $29,000. 6.09% of the stock is currently owned by institutional investors.

GeoVax Labs Stock Performance

Shares of NASDAQ:GOVX traded down $0.07 during trading on Friday, reaching $0.83. 460,713 shares of the stock traded hands, compared to its average volume of 604,785. The stock has a market cap of $11.48 million, a P/E ratio of -0.15 and a beta of 3.70. The stock has a 50-day moving average of $1.36 and a two-hundred day moving average of $1.94. GeoVax Labs has a 52-week low of $0.73 and a 52-week high of $11.18.

GeoVax Labs (NASDAQ:GOVX) last issued its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating the consensus estimate of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.38 million. Sell-side analysts expect that GeoVax Labs will post -4.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on GOVX shares. HC Wainwright reissued a “buy” rating and set a $8.00 price target on shares of GeoVax Labs in a research report on Wednesday. D. Boral Capital reissued a “buy” rating and issued a $18.00 price target on shares of GeoVax Labs in a research report on Thursday, April 10th. Finally, Alliance Global Partners cut their price target on GeoVax Labs from $15.00 to $8.50 and set a “buy” rating on the stock in a research note on Tuesday, April 15th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat, GeoVax Labs has a consensus rating of “Buy” and an average price target of $12.90.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.